Scinovex
articleTop 1% cited

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

The Journal of Pediatrics · 2003 · Vol. 143(4) · pp. 532–540
Timothy F. FeltesAllison K. CabalkaH. Cody MeissnerFranco M. PiazzaDavid A CarlinFranklin H. TopEdward M. ConnorHenry M. Sondheimerfor the Cardiac Synagis Study Group
Respiratory viral infections researchMechanical Circulatory Support DevicesCongenital Heart Disease StudiesPalivizumabMedicinePlaceboAdverse effectHeart diseasePediatricsRandomized controlled trialRespiratory systemAnesthesiaInternal medicine

MeSH terms

PalivizumabAntibodies, MonoclonalAntiviral AgentsDouble-Blind MethodHeart Defects, CongenitalHospitalizationHumansRespiration, ArtificialRisk FactorsComorbidityRespiratory Syncytial Virus InfectionsAntibodies, Monoclonal, Humanized
Citations
820
FWCI
17.67
field-weighted impact
References
22
Percentile
99%
vs. same field & year
Citations per year
Cited by
Approved Antiviral Drugs over the Past 50 Years
Clinical Microbiology Reviews · 2016 · 1,404 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.